JENTADUETO® XR

Drug Information Related Patent
Hold Company
BOEHRINGER INGELHEIM
Dosage and Administration
TABLET, EXTENDED RELEASE;ORAL
Specification
2.5MG;1GM
5MG;1GM
Indication
JENTADUETO® XR is considered as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
API
LINAGLIPTIN
METFORMIN HYDROCHLORIDE
API Structure
Drug Patent
Patent NoExpiration Date
100223792029/4/2
10022379*PED2029/10/2
74079552025/5/2
7407955*PED2025/11/2
86739272027/5/4
8673927*PED2027/11/4
88838052025/11/26
8883805*PED2026/5/26
91557052030/5/21
9155705*PED2030/11/21
91738592027/5/4
9173859*PED2027/11/4
94150162029/4/2
9415016*PED2029/10/2
95550012033/3/6
9555001*PED2033/9/6
API Patent
Patent NoExpiration Date
100223792029/4/2
10022379*PED2029/10/2
74079552025/5/2
7407955*PED2025/11/2
88838052025/11/26
8883805*PED2026/5/26

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

CONTACT US
  • Tel:
  • E-mail:
  • Address:
  • WhatsAPP
    WhatsAPP
Privacy Policy | Cookie Policy
Copyright © Protheragen. All Rights Reserved.
Member of
dcat
CERTIFICATION
dcat
dcat dcat dcat dcat
Top